Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan. Immutep will provide full technical support for the development of IMP321, a LAG-3Ig fusion protein that has completed a Phase I/II trial combined with chemotherapy in first-line metastatic breast cancer. Immutep and Eddingpharm plan to develop the product for breast cancer as well as other first-line metastatic indications.

“We have been very impressed by the dynamic and innovative approach of Eddingpharm, and believe them to have the capability of driving the development of IMP321 in China,” said John Hawken, CEO. “Immutep is continuing the development of IMP321 in Europe and the USA.”

Founded in 2001, Eddingpharm is actively collaborating with companies to introduce new products into China’s pharmaceutical market. The company reports that it has built up a competitive product portfolio and pipeline in the four major therapeutic areas: medical nutrition, oncology, anti-infective, and respiratory.

Last month, it entered into a licensing, development, and commercialization agreement with Syndax Pharmaceuticals for exclusive rights to develop, market, and sell entinostat, which targets advanced, treatment-resistant cancers, in China and certain other Asian countries/regions.

In April, it entered into a collaboration with GlaxoSmithKline wherein it obtained the exclusive right in mainland China to import, market, promote, distribute, and sell Tykerb, a treatment for advanced or metastatic breast cancer that was recently approved by the China State Food and Drug Administration.

Also in April, Eddingpharm and Chiesi Farmaceutici entered into a joint venture agreement to establish Chiesi Edding Hong Kong Limited. Chiesi Edding will leverage the marketing platform of Eddingpharm to facilitate the commercialization of the two key products of Chiesi Farmaceutici in the respiratory therapeutic area in China.

Previous articleA*STAR, Debiopharm Team Up to Develop Epigenetic Cancer Target
Next articleU.S.-Based Trio Named Joint Winners of Nobel Prize in Physiology or Medicine